Rana R. McKay, MD

Rana R. McKay, MD, medical oncologist, assistant professor, Moores Cancer Center at the University of California, San Diego, discusses unmet needs for patients with renal cell carcinoma (RCC).

Rana R. McKay, MD, medical oncologist, assistant professor, Moores Cancer Center at the University of California, San Diego, discusses combinations in renal cell carcinoma.

Rana R. McKay, MD, medical oncologist, assistant professor, Moores Cancer Center at the University of California, San Diego, discusses advances in the treatment of metastatic renal cell carcinoma.

Rana R. McKay, MD, assistant professor of medicine and medical oncologist at the University of California, San Diego, discusses the FDA approval of cabozantinib (Cabometyx) in the frontline setting for patients with renal cell carcinoma (RCC).

Rana R. McKay, MD, medical oncologist, assistant professor, Moores Cancer Center at the University of California, San Diego, discusses immunotherapy trials in renal cell carcinoma.

Rana R. McKay, MD, medical oncologist, assistant professor, Moores Cancer Center at the University of California, San Diego, discusses the CheckMate-214 study in renal cell carcinoma.

Rana R. McKay, MD, discusses a study looking at statins and survival outcomes in patients with metastatic renal cell carcinoma.

Rana R. McKay, MD, a clinical oncology fellow at Dana-Farber Cancer Institute, Boston, Massachusetts, explains the mechanism of action of dutasteride and its role in a phase II trial in which abiraterone acetate was combined with dutasteride in men with metastatic castration-resistant prostate cancer